Dexcom Ventures

Jason Halac, co-founder and Managing Director, leads technology scouting and strategic pipeline development for Dexcom Ventures. He is supported by Analyst Adam Seivert, who handles co-investor networking, sourcing, due diligence, and portfolio management. The small team structure means Halac is directly involved in investment decisions, reflecting the unit's tight alignment with Dexcom's corporate strategy.

Dexcom Ventures is the corporate venture capital arm of Dexcom, Inc., the publicly traded continuous glucose monitoring company. It invests directly from the corporate balance sheet into startups whose technologies are adjacent to or potentially synergistic with Dexcom's core biosensing and health data business. The unit is not a separate fund with outside limited partners.

Based on its disclosed portfolio of direct investments into companies such as Epitel, Beta Bionics, and Nutromics, Dexcom Ventures focuses on direct equity stakes in startups. There is no public evidence that it makes commitments as a limited partner into external venture funds. Its model is to take direct positions where it can add strategic value alongside its capital.

Dexcom Ventures seeks out promising transformational technology platforms, often describing its bets as contrarian or symmetrical. The specific stage preference is not publicly disclosed, but its portfolio includes companies ranging from early commercial-stage ventures like Epitel and Nutromics to more developed platforms approaching or having achieved regulatory milestones, such as Beta Bionics.

The unit concentrates on biosensing technology, data-driven healthcare, and adjacent medical device fields. Its portfolio features continuous molecular monitoring (Nutromics), remote patient monitoring (BiointelliSense), AI-powered weight management combining CGM data (Signos), medical device cybersecurity (Medcrypt), and automated insulin delivery (Beta Bionics). The common thread is sensor-driven, personalized health data.